Reimbursement Scheme Jardiance® - Chronic Kidney Disease

20 July 2023

Reimbursement Scheme Jardiance® - Chronic Kidney Disease

Arrangement for reimbursement by TerugBetaalRegeling Jardiance® (empagliflozin) 10 mg for patients with chronic kidney disease without type 2 diabetes mellitus.

Jardiance (empagliflozin) has been given an extension of the indication for chronic kidney disease.  

The health insurer already reimburses Jardiance (empagliflozin) 10 mg Jardiance (empagliflozin) for chronic kidney disease patients with T2D. Currently, there is no regular reimbursement for Jardiance (empagliflozin) for chronic kidney disease patients without T2D. The manufacturer has therefore decided to refund the full costs for the patient via TBR Nederland.


The following steps ensure that your patients can use the reimbursement scheme:

- The pharmacy checks whether the patient is eligible for regular reimbursement.

- Not eligible? The pharmacy shall then verify that the patient meets the following criteria:

  • Chronic kidney disease patient without T2D
  • A prescription by a health care professional is provided
  • Jardiance (empagliflozin) 10 mg dose

Pharmacists or patients can declare the costs, provided that the prescription was written after July 24th 2023,

Who can submit a claim

Pharmacies, patients, or their caregivers can claim the costs of Jardiance (empagliflozine) 10 mg for the treatment of chronic kidney disease without T2D either online or by post, with online being the faster option.

More information on Jardiance (empagliflozin) 10 mg webpage

You are currently offline. Some pages or content may fail to load.